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Abstract
Angiogenesis is an essential process for normal skeletal muscle function. There is a growing body of evidence suggesting
that thrombospondin-1 (TSP-1), a potent antiangiogenic protein in tumorigenesis, is an important regulator of both
physiological and pathological skeletal muscle angiogenesis. We tested the hypothesis that chronic exposure to a TSP-1
mimetic (ABT-510), which targets the CD36 TSP-1 receptor, would decrease skeletal muscle capillarity as well as alter the
balance between positive and negative angiogenic proteins under basal conditions. Osmotic minipumps with either ABT-
510 or vehicle (5% dextrose) were implanted subcutaneously in the subscapular region of C57/BL6 mice for 14 days. When
compared to the vehicle treated mice, the ABT-510 group had a 20% decrease in capillarity in the superficial region of the
gastrocnemius (GA), 11% decrease in the plantaris (PLT), and a 35% decrease in the soleus (SOL). ABT-510 also decreased
muscle protein expression of vascular endothelial growth factor (VEGF) in both the GA (2140%) and SOL (262%); however
there was no change in VEGF in the PLT. Serum VEGF was not altered in ABT-510 treated animals. Endogenous TSP-1 protein
expression in all muscles remained unaltered. Tunnel staining revealed no difference in muscle apoptosis between ABT-510
and vehicle treated groups. These data provide evidence that the anti-angiogenic effects of TSP-1 are mediated, at least in
part, via the CD36 receptor. It also suggests that under physiologic conditions the TSP-1/CD36 axis plays a role in regulating
basal skeletal muscle microvessel density.
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Introduction
Physiologic angiogenesis and homeostasis of adult blood vessels
is a complex process that is highly regulated by a balance between
positive and negative angiogenic proteins. While there is a
substantial body of evidence on the role positive angiogenic
factors, such as vascular endothelial growth factor (VEGF) [1,2,3],
the role of negative angiogenic factors is incomplete and poorly
understood [4].
There are a number of known angiogenic inhibitors, of which
thrombospondin-1 (TSP-1) is thought to play a prominent role in
skeletal muscle angiogenesis [4]. TSP-1 is a large (450 kD)
extracellular protein that has a wide array of functions [5]. First
discovered for its role in wound healing and platelet activation, it
also has important roles in apoptosis, inflammation, nitric oxide
signaling, and inhibition of positive angiogenic proteins
[6,7,8,9,10]. Acting through CD36 (one of its receptors), TSP-1
has been shown to prevent endothelial cell adhesion, growth, and
migration, as well as increase apoptosis [11,12,13]. The anti-
angiogenic effects of TSP-1 in cancer pathology are well
established. For example, a reduction in TSP-1 has been shown
to increase tumor vessel growth, whereas pharmacological
administration of several different TSP-1 mimetics has helped
decrease tumor size and disease progression in animal models
[14,15,16,17].
Under physiologic conditions, TSP-1 expression has been
shown to be responsive to exercise [18,19], which suggests that
TSP-1 may play a role in regulating exercise-induced skeletal
muscle angiogenesis. TSP-1 KO mice have elevated skeletal
muscle capillarity compared to wild-type mice, suggesting a critical
role for TSP-1 in the physiological maintenance of capillaries [4].
Evidence in rats also shows that hindlimb unloading increases
TSP-1 in association with decreases in skeletal muscle capillarity
[3]. Recently, TSP-1 and it’s receptor CD47 have also been
suggested to play a pivotal role in skeletal muscle mitochondrial
biogenesis, and therefore it is likely to be important in overall
skeletal muscle function and adaptation to exercise stress [20].
Given the growing data implicating that importance of TSP-1
as a key angiogenic regulator in skeletal muscle, we sought to
determine the consequences of chronically stimulating the TSP-1
pathway using ABT-510. ABT-510 is a mimetic of the conserved
type I repeat region of TSP-1 which has been shown previously to
inhibit angiogenesis through the CD36 receptor [12,13,21]. ABT-
510 has been synthesized to have a longer half life in circulation
than the native type I repeats of TSP-1 which allows for increased
chronic stimulation of the TSP-1/CD36 pathway [22]. ABT-510
has been shown to be a potent inhibitor of vascular growth in
tumorigenesis both in vitro and in vivo [15,23,24,25,26,27,28],
which has been attributed to its binding to the CD36 receptor.
Using this peptide we aimed to examine whether increased
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stimulation of the CD36 arm of the TSP-1 pathway affected
skeletal muscle structure and function. Given that TSP-1 is a
negative angiogenic regulator, we hypothesized that mice subject-
ed to the ABT-510 would have lower skeletal muscle capillarity,
mirrored by an altered balance between positive and negative
angiogenic proteins.
Methods
Animals
This study used 10–12 week old male C57BL/6 mice purchased
from Jackson Laboratories (Strain no. 000664, C57BL/6J, Bar
Harbor, ME). Mice were randomly selected to be placed in two
groups (control, n = 8; experimental n = 8). All procedures that
involved animals were approved by the West Virginia University
Institutional Animal Care and Use Committee.
Exercise Testing Protocol
Whole body exercise capacity was assessed using a graded
maximal exercise test (max test) 48 hours before pump implan-
tation and then again 48 hours before muscle harvest (12 days
after implantation). This was done to ensure that the exercise bout
did not influence protein levels in muscles harvested on the final
study day (Day 14) [18]. Maximal run test procedure: mice were
given a 5 minute warm-up (speed ,4 m/min) at a 10 degree
incline on a commercially available rodent treadmill (Columbus
Instruments, Columbus, OH). After the warm-up period, the
treadmill was increased 2 m/min every 30 seconds until the
animals reached exhaustion. Exhaustion was defined by a single
observer as the inability of the animal to stay on the treadmill at a
given speed, and/or more than 3 seconds spent on the shock grid.
Animals were encouraged to run as fast and as long as possible by
using forced air and a weak electrical deterrence. Final run time
and velocity were recorded and compared between groups.
Osmotic Pump Drug Delivery
The TSP-1 mimetic ABT-510 was generously provided by
Abbott (Abbott, IL). This compound was chosen for use in this
study based on previous and preliminary work showing its
effectiveness in decreasing capillarity in tumors, both in vitro and
in vivo [15,22,23,24,25,29,30]. ABT-510 was dissolved in 5%
dextrose (vehicle) over a 48 hour period to ensure the compound
was fully dissolved, and then inserted into mini-osmotic pumps
(Model 1002, Alzet Osmotic Pumps, Cupertino, CA,). Pumps were
filled with either the drug or vehicle solution 24 hours in advance
of implantation as per manufacture instructions. We delivered the
maximum concentration of 30 mg/kg/day based on the maxi-
mum pump capacity (100 mL), the mass of the animals, and the
solubility of the drug (ABT-510 solubility curves [22]). Pumps were
surgically inserted (flow-moderator first) subcutaneously in the
scapular region while the mice were under anesthesia (2%
isoflurane). The surgical site was disinfected with iodine and
closed using sutures. Animals were then housed individually and
observed daily for the remainder of the study for pain or distress.
Pumps remained in the animals for 14 days, after which they were
sacrificed and tissue/organ samples were collected and stored at
280u for later analysis.
Morphometry
Hindlimb skeletal muscle was surgically excised and frozen in
isopentane cooled by liquid nitrogen. Frozen tissue was cut using a
220uC cyromicrotome (Jung-Reichert Cryocut 1800: Cambridge
Instruments, Germany) to yield 10 mm transverse sections. Great
care was taken to ensure the cryosectioned muscles were cut along
the transverse plane. Sections were stained for dipeptidly-peptidase
IV (DPP IV) and alkaline phosphatase (AP) following the method
of Lojda (1979), as applied to skeletal muscle tissue [31,32]. A light
microscope (Zeiss primo star, Zeiss, Oberkochen, Germany) was
used to digitally acquire (Axiocam IC c3, Axiovision 4.8.2.0, Zeiss,
Oberkochen, Germany) 206 images of the gastrocnemius,
plantaris, and soleus. Capillary and myofiber counting was
performed by a single individual blinded to group identification.
For the gastrocnemius muscle, we obtained images in a
checkerboard fashion across the entire muscle, thus both
superficial and deep regions within the gastrocnemius could be
included in the analysis. For the plantaris and soleus muscles,
respectively, the entire muscle was imaged and analyzed. Counting
was performed by visualization from acquired images using a
custom program in MATLAB (version 7.0.0.27, The Mathworks,
MA, USA) allowing the operator to visually mark and count the
capillaries and fibers on each image. Capillary-to-fiber ratio (C:F,
number of capillaries/number muscle fibers), capillary density
(CD, number of capillaries/mm2 muscle fiber area), and fiber
cross sectional area (FCSA) were separately calculated for the
gastrocnemius (GA), soleus (SOL), and plantaris (PLT) (n = 33–
101 images/muscle/group).
Protein Analysis
GA, SOL, and PLT muscles from each group were excised and
flash frozen in liquid nitrogen. They were then separately
homogenized in a lysis buffer containing 50 mM Tris/HCl
(pH 7.4), 150 mM NaCl, 0.5% Triton X-100, and protease
inhibitors (Complete Tablet, Roche Applied Science, Indianapolis,
IN). Homogenates were centrifuged at 4uC, at 8,000 g for
10 minutes, and supernatants removed and placed in new tubes.
Blood samples were obtained from the heart and allowed to
coagulate on ice. They were then centrifuged at 3000 g for
10 minutes and flash frozen in liquid nitrogen. Total protein was
measured by bradford assay (#23236 Pierce Coomassie Plus
Protein Assay Kit, Thermo Scientific, Rockford, IL).
Quantification of VEGF was made from a total of 100 mg of
protein using a commercially available ELISA kit according to the
manufactures instructions (# MMV00, R&D Systems, Minneap-
olis, MN, USA). Quantification of VEGFR-2 and P-VEGFR-2
were made from a total of 100 mg of protein using a commercially
available ELISA kit according to the manufactures instructions (#
7335S, #7340S, Cell Signaling, Danvers, MA, USA). TSP-1 and
CD36 were analyzed via western blot. In brief, samples were
separated on a 3–8% SDS-PAGE (NuPAGE Novex 3–8% Tris-
Acetate Midi Gel, Invitrogen, Burlington, ON, Canada) and
blotted onto a 0.45 mm nitrocellulose membrane (Pierce nitrocel-
lulose membrane, Thermo Scientific, Rockford, IL). After
blocking with 5% fat-free milk, membranes were probed using
antibodies against TSP-1 (1:1000, clone A6.1, #399300, Invitro-
gen, Burlington, ON, Canada), b-tubulin (1:1000, #2148, Cell
Signaling), CD36 (1:250 #552544, BD Pharmingen, Franklin
Lakes, NJ, USA), secondary HRP-conjugated anti-mouse (1:1000,
#p0260, Dako, GE Healthcare, Piscataway, NJ) and secondary
HRP-conjugated anti-rabbit (1:1000, #p0217, Dako). Proteins
were visualized using chemiluminescence detection (Pierce ECL,
Thermo Scientific, Rockford, IL) and digitally imaged (G:BOX
Gel imager, Syngene, Cambridge, UK) using Genesnap software
(Ver. 7.01, Syngene, Cambridge, UK). Equal protein loading was
verified by immunodetection of b-tubulin as our loading control.
Quantification of protein expression levels were carried out using
NIH Image J Software (v1.62) and expressed as densitometric
arbitrary units (AU).
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Apoptosis
Nuclei exhibiting apoptotic changes were identified by TdT-
mediated dUTP nick end labeling (TUNEL) according to the
manufacturer’s recommendations (Roche Molecular Biochemi-
cals, Pleasanton, CA). Briefly, muscle cross sections were cut on a
cryostat (10 mm) and fixed in 4% paraformaldehyde at room
temperature, blocked in 3% H2O2 in 100% methanol at room
temperature, and permeabilized in 0.1% Triton X and 0.1%
sodium citrate. TUNEL reaction mix was added in a 1:7.5
dilution, and the sections were incubated at 37uC for 1 h. Sections
were reacted with fluorescein antibody for 30 min at 37uC, and
substrate was added for color development. To control for false-
positives, samples were then counter stained by DAPI staining to
identify the nucleus. TUNEL staining was performed using a
fluorescein TUNEL kit at 1:7.5 dilution as recommended by the
manufacturer (Roche Molecular Biochemicals, Pleasanton, CA).
Positive nuclei were counted, and at high power (6400), it was
determined whether they were associated with the myofiber or
with the interstitial space. The number of positive nuclei is
expressed per whole muscle section. Positive controls were created
using a DNase treatment of 1 serial section (# AM1906, DNA-free,
Ambion, Austin, TX). Negative controls were created by staining 1
serial section only for DAPI without TUNEL staining. This
resulted in each sample containing 1 negative, 1 positive, and 2
experimental sections per slide.
Statistics
All data are presented as means+/2SEM. To examine body
mass, organ masses, muscle capillarity and molecular responses we
used a student’s T-test. A repeated measures ANOVA was used to
analyze the maximal running test. An alpha level at P,0.05 was
selected for statistical significance.
Results
Exercise Testing and Morphometry
Body and Muscle Mass. There was no significant difference
in the absolute body or individual hindlimb muscle masses
between ABT-510 (mimetic) and vehicle treated groups (Table 1).
Heart and skeletal muscle normalized to body mass were not
different between the groups (Table 1).
Maximal Running Test. There was no difference in
maximal running speed between vehicle and mimetic treated
animals pre- or post-treatment.
Morphometry. In the superficial region of the gastrocnemius
(GA) muscle there was a 20% decrease in C:F (P#0.05) and a
similar trend in CD (25% decrease, P = 0.055) in the mimetic
group compared to vehicle (Figure 1 & 2). There was no statistical
difference in C:F of the deep portion of the GA between groups,
however there was a significant 25% decrease in CD (P#0.05).
FCSA was not significantly different between groups in either
portions of the GA.
In the plantaris (PLT) muscle, there was a 11% decrease in the
C:F in the PLT in the mimetic group compared to vehicle
(P#0.05) (Figure 3). There was no difference in CD or FCSA in
the PLT.
In the soleus (SOL) muscle, there was a 35% decrease in the C:F
in the SOL in the mimetic group compared to vehicle (P#0.01)
(Figure 3). There was no difference in CD (P = 0.08) or FCSA
(P = 0.09).
Endogenous VEGF, VEGFR-2, p-VEGFR-2, TSP-1, and CD36
Levels
Skeletal muscle VEGF protein expression was decreased by
147% and 62% in the GA and SOL respectively (P#0.05,
Figure 4). In contrast, no significant change in VEGF protein
expression was seen in the in the PLT. Serum VEGF levels were
unchanged between ABT-510 and vehicle treated animals.
Total VEGFR-2 and phorphylated-VEGFR-2 (p-VEGFR-2)
levels were also assessed in the GA. There was no difference in
total VEGFR-2 levels, p-VEGFR-2 levels, or a ratio of VEGF-
R2/p-VEGF-R2 between ABT-510 and vehicle treated mice (data
not shown).
Endogenous TSP-1. protein expression of endogenous TSP-
1 was not significantly different in any of the muscles analyzed
(SOL, PLT, GA) between the treated groups (data not shown).
CD36 levels. There was no difference in the receptor levels of
CD36 in the GA as assessed by western blot (data not shown).
Table 1. Muscle and Body Masses.
Vehicle ABT-510
Body Mass (g) 27.561.23 27.160.87
GA (mg) 136.864.56 140.864.09
PLT (mg) 19.760.90 19.060.53
SOL (mg) 7.760.47 7.86.048
HRT (mg) 123.565.76 134.365.82
GA/BM (mg/g) 5.060.07 5.260.12
PLT/BM (mg/g) 0.7260.04 0.7060.02
SOL/BM (mg/g) 0.2960.01 0.2860.01
HRT/BM (mg/g) 4.460.26 5.060.17
Values: Mean 6 Standard Error.
*P = 0.05.
doi:10.1371/journal.pone.0055953.t001
Figure 1. Representative figures of the histology sections. A)
Superficial Gastrocnemius Muscle B) Deep Gastrocnemius Muscle C)
Plantaris Muscle, D) Soleus Muscle.
doi:10.1371/journal.pone.0055953.g001
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Apoptosis
Apoptosis was assessed using TUNEL staining for fragmented
DNA. There was no difference in the number of TUNEL positive
nuclei in any of the muscles between the two treated groups
(Figure 5).
Discussion
The main finding of this study is that chronic exposure to the
TSP-1 mimetic ABT-510 significantly decreases skeletal muscle
capillarity (Figure 1). To our knowledge, these are the first data to
show that chronic stimulation of the TSP-1/CD36 pathway in
healthy mammals results in decreased skeletal muscle capillarity.
These data are consistent with the anti-angiogenic function of
TSP-1 and, more importantly, support the notion that TSP-1
through its CD36 receptor is a critical regulator of skeletal muscle
capillarity under physiologic conditions. Indeed, when coupled
with the previous observation that loss of TSP-1 increases skeletal
muscle capillarity (25) these data provide evidence that the actions
of TSP-1 directly influence homeostatic maintenance and/or
development of skeletal muscle microvessels.
Skeletal muscle capillarity is decreased in mimetic treated
mice
TSP-1 has been shown previously to be important in
maintaining skeletal muscle capillarity, where TSP-1 KO mice
have approximately 2 fold the number of capillaries as WT
controls [33]. Further, TSP-1 has been shown to be important in
maintaining capillarity with hindlimb unloading [34]. In this
manuscript we build upon this small body of evidence for the
importance of TSP-1 in the context of the basal regulation of
angiogenesis.
The actions of TSP-1 are complex and multifunctional, due in
large part to the diversity of receptors it binds, such as lipoprotein
receptor-related protein 1 (LRP-1), CD47, and CD36 [11,35].
Our use of this the TSP-1 mimetic ABT-510, which is a potent
CD36 binding peptide, resulted in a decrease in capillarity across
three different distinct skeletal muscles. This suggests that TSP-1s
Figure 2. Superficial gastrocnemius capillarity, but not deep, is decreased in the ABT-510 group. Chronic administration of ABT-510
30 mg/kg/day decreased capillary to fiber ratio (C:F) and capillary density (CD) in the superficial gastrocnemius (GA). Despite a similar trend, no
significant changes in capillarity were seen in the deep GA. There was no change in fiber cross sectional area in either the deep or superficial portions
of the GA. * = P#0.05.
doi:10.1371/journal.pone.0055953.g002
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anti-angiogenic properties in skeletal muscle involves a CD36
mediated mechanism. Indeed, this is consistent with the physio-
logical activity of CD36 where TSP-1 binding to CD36 has been
shown to be anti-proliferative, anti-angiogenic, and pro-apoptotic
[12]. The importance of the TSP1/CD36 pathway has been
proven in tumorigenesis, where down regulation of TSP-1 and its
binding to CD36 results in a pro-tumorigenesis environment and
increase in tumor size [14,36,37,38]. Here we show similar actions
in skeletal muscle under physiological conditions. This suggests a
putative role for TSP-1 in decreasing vascularity across multiple
tissues, and not just in tumors.
Given these findings, it is tempting to speculate that elevated
skeletal muscle TSP-1 may serve as a biomarker for skeletal muscle
dysfunction associated with several chronic conditions known to
result in muscle capillary rarefaction, such as that found in
diabetes [39,40], and chronic heart and lung disease [41]. It may
even be that therapeutic interventions to limit basal TSP-1
expression and/or reduce circulating levels of TSP-1 could be
clinically exploited to attenuate the decrements in skeletal muscle
function often accompanying these diseases.
Chronic stimulation of the TSP1/CD36 pathway
decreases VEGF
It has been shown previously that TSP-1 can counter the effects
of VEGF by multiple mechanisms; including interacting directly
with VEGF protein and disrupting its actions at the receptor level
[42,43,44,45,46]. For example, TSP-1 has been suggested to bind
VEGF via its type I repeat region (or 3TSR). Once bound the
protein heterodimer is internalized by the scavenger receptor low
density lipoprotein receptor-related protein 1 (LRP-1). Here, we
show that a chronic administration of ABT-510 (a TSP-1 type I
repeat mimetic), results in a decrease in total VEGF protein in
both the gastrocnemius muscle and the soleus muscle, along with
the decrease in capillarity. It is unclear why a similar decrease in
VEGF protein was not seen in the PLT which also showed
decreased capillarity, nevertheless these data support previous
Figure 3. Plantaris and soleus capillarity is decreased in the ABT-510 group. Chronic administration of ABT-510 30 mg/kg/day decreased
capillary to fiber ratio (C:F) in the plantaris muscle (PLT) but did not decrease capillary density (CD). ABT-510 decreased capillary to fiber ratio (C:F) and
capillary density (CD) in the soleus (SOL). There was no change in fiber cross sectional area in either the PLT or SOL muscle. * = P#0.05.
doi:10.1371/journal.pone.0055953.g003
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studies suggesting that TSP-1 may be binding and sequestering
VEGF – resulting eventually in internalization and biological
inactivation [42,43,44,45,46]. Explanations for the reduction in
VEGF may also involve suppression of VEGF production and/or
VEGF signaling. For example, there is a growing body of evidence
showing that the internalization of the VEGF/VEGFR-2 complex
by endocytosis results in downstream activation of several different
signaling pathways [47]. There is also evidence that both CD36
and CD47 can associate with VEGFR-2, and when TSP-1 is
present this association can prevent the VEGF ligand binding to its
receptor, as well as inducing receptor dephosphorylation and
preventing dimerization [13,21,48,49]. In this way, TSP-1 could
prevent activation and/or endocytosis of the VEGF receptor,
blocking yet another biologically active arm of VEGF/VEGF-R
complex. Regardless of the mechanism, our data supports the
notion that TSP-1 likely plays a regulatory role involving VEGF,
thereby enhancing its already potent inherent anti-angiogenic
capacity.
In endothelial cells, TSP-1 can also disrupt VEGF actions at the
receptor level by dephosphorylating the important receptor
VEGFR-2 (Flk-1) [50]. TSP-1 can disrupt VEGFR-2 activation
by binding the CLESH region of CD36, triggering a cascade of
events which results in direct binding of VEGFR-2, and a resultant
decrease in tyrosine phosphorylation of VEGFR-2 [12,13,21].
This includes dephosphorylating the important tyrosine 1175
region; which is critical to initiate downstream VEGF signaling.
While it has also been shown previously that ABT-510 significantly
decreases the amount and phosphorylation status of VEGFR-2 in
endothelial cells in vitro [24,51], in vivo we found no significant
change in the phosphorylation levels of tyrosine 1175 of VEGFR-
2. Given that the mimetic is a type I repeat, and that total VEGF
protein levels were decreased, we were surprised that VEGFR-2
phosphorylation was also not decreased. But, because we only
have one time point, it could be that levels of phosphorylation
were lower earlier in the chronic dosage but by the end of the
study returned to normal levels. While ABT-510 has been shown
to decrease VEGFR-2 phosphorylation in tumors [24], it may be
that this response is different in skeletal muscle under physiological
conditions. It could also be that phosphorylation status in vivo is not
lowered by endogenous TSP-1 (or the addition of a mimetic),
rather TSP-1 limits or prevents an increase in phosphorylation
levels with a VEGF stimulus. This is yet to be elucidated.
Administration of ABT-510 did not significantly alter endoge-
nous levels of TSP-1 in skeletal muscle, indicating that there was
no feedback response from the mimetic binding to CD36 to alter
endogenous TSP-1 levels in skeletal muscle. However, the
Figure 4. Skeletal muscle VEGF protein content is decreased in the ABT-510 group, but not serum levels. Chronic administration of the
mimetic (ABT-510 30 mg/kg/day) decreased VEGF protein in the GA, and SOL muscles of C57/BLK6 mice. There was no change in the PLT muscle or in
Serum levels. * = P#0.05.
doi:10.1371/journal.pone.0055953.g004
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reduction of skeletal muscle VEGF protein levels in association
with the mimetic adds support to the idea that physiologic
angiogenesis is controlled by a balance between both positive and
negative angiogenic factors, particularly VEGF and TSP-1. It
would have been interesting to deliver a higher dose of ABT-510
(.30 ug/kg/day) which may have resulted in greater reductions
in muscle VEGF and capillarity; however the dose used was the
maximum we could deliver using the small pumps suitable for
mice and the 2-week duration we sought. Although shorter
duration would allow greater concentrations of drug delivery, we
opted to deliver the drug for 14 days to ensure that vascular
remodeling would have sufficient time to occur. It could be
hypothesized that tipping the scale towards an anti-angiogenic
state (stimulated by the presence of ABT-510) would result in a
response of positive angiogenic factors to counter this challenge.
However, at least with respect to VEGF this was not the case. A
decrease in VEGF and no change in endogenous TSP-1 suggests
that the muscle has been pushed towards an anti-angiogenic
phenotype.
Regardless of mechanism, these data show that the altered
angiogenic state of the skeletal muscle can be driven by an increase
in a TSP-1 mimetic. The resulting decrease in capillarity
establishes the importance of TSP-1/CD36 pathway in maintain-
ing and regulating basal skeletal muscle microvessel density.
Skeletal muscle and endothelial apoptotic levels do not
differ between groups
In addition to its anti-angiogenic properties, TSP-1 is also been
known to promote apoptosis [6,52,53,54,55,56,57,58]. TSP-1 is
known to induce apoptosis through the CD36 pathway, as shown
in previous studies, including those using ABT-510 [5,24,59].
Endothelial apoptosis is a natural mechanism by which capillary
regression occurs [60,61,62,63], and has been shown to be central
in muscle atrophy during some pathologies, aging, and disuse
[64,65,66,67,68]. Knowing this, we performed TUNEL staining to
look at end stage apoptosis (DNA fragmentation) in all three of the
excised muscles. Surprisingly, we found no evidence of apoptosis
in any of the muscles, either myocyte or endothelial. The reason
for this remains unclear. This is, however, the first in vivo report of
ABT-510s affects on skeletal muscle and it could be that ABT-510
is not sufficient to induce myocyte apoptosis in skeletal muscle
under these conditions. Indeed, much of the work with TSP-1 and
apoptosis pertains to cancer models (e.g. tumorigenesis), endothe-
lial cells, and is typically done in vitro. It is possible that TSP-1 is
not as potent a pro-apoptotic protein in skeletal muscle as that seen
in endothelial cells or tumors. This is supported by the finding that
there was no change in muscle fiber cross-sectional area (Figures 2
and 3). Whether or not the ABT-510, or the TSP-1/CD36 axis,
alters in vivo skeletal muscle myocyte apoptosis will require further
study.
However, this does not explain why we saw no endothelial cell
apoptosis. As mentioned previously, our study only examines one
time point. It is possible that apoptosis occurred at an earlier time
point than our assessment at the 14 day time point. Indeed, it has
been shown previously that hindlimb unloading results in capillary
loss in as little as 5 days [34]. If changes in endothelial cell number,
and therefore total vasculature, are occurring by 5–7 days it may
not be surprising that evidence of apoptosis has been lost by the
end of the study (14 days). That is, perhaps apoptosis has already
occurred, the cells cleared from the tissue, and the architecture of
the vascular network at 14 days has already returned to a new
steady state condition absent of apoptotic nuclei. We have yet to
elucidate this and more experimentation is needed to determine
exactly when apoptosis and regression is occurring.
Summary
In conclusion, we provide evidence for the importance of TSP-
1/CD36 pathway in regulating basal skeletal muscle capillarity by
showing that a chronic dosage of a TSP-1 mimetic for the CD36
pathway decreases skeletal muscle capillarity and VEGF expres-
sion. We did not find any differences in the VEGFR-2 expression
or its phosphorylation status, nor was there greater skeletal muscle
apoptosis. These data show that, despite the multifunctional effects
of TSP-1 and its CD36 receptor, the primary consequence of
elevating circulating TSP-1 (i.e. using a TSP-1 mimetic targeted to
its CD36 receptor) relates to its anti-angiogenic function. These
data may be useful in exploring therapeutic interventions for
individuals with skeletal muscle dysfunction resulting from
capillary regression.
Acknowledgments
The authors wish to thank Kathleen Roberts, W. Kyle Mandler, Sara
Olenich, and Dharendrah Thapa for their assistance in the laboratory in
preparing pumps and processing the tissues. We would also like to thank
Dr. Josef Anrather of The Weill Cornell Medical College for his help and
advice on CD36 analysis.
Author Contributions
Conceived and designed the experiments: IMO GNA. Performed the
experiments: GNA DF JCS. Analyzed the data: GNA IMO. Contributed
reagents/materials/analysis tools: IMO. Wrote the paper: GNA IMO.
Figure 5. There is no difference in skeletal muscle apoptosis
between the mimetic and control groups. TUNEL staining shows
that chronic administration of the mimetic (ABT-510 30 mg/kg/day) did
not increase or decrease skeletal muscle apoptosis in any of the muscles
tested. Representative GA samples, PLT and SOL data not shown. A)
Representative mimetic GA B) Representative positive control mimetic
GA C) Representative control GA D) Representative positive control
vehicle GA.
doi:10.1371/journal.pone.0055953.g005
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